ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

SNG Synairgen Plc

3.50
-0.375 (-9.68%)
26 Sep 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Synairgen Plc LSE:SNG London Ordinary Share GB00B0381Z20 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.375 -9.68% 3.50 3.01 3.99 3.99 3.60 3.71 586,442 16:35:15
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 0 -8.41M -0.0418 -0.95 7.8M
Synairgen Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker SNG. The last closing price for Synairgen was 3.88p. Over the last year, Synairgen shares have traded in a share price range of 3.00p to 10.62p.

Synairgen currently has 201,374,975 shares in issue. The market capitalisation of Synairgen is £7.80 million. Synairgen has a price to earnings ratio (PE ratio) of -0.95.

Synairgen Share Discussion Threads

Showing 37776 to 37798 of 99400 messages
Chat Pages: Latest  1516  1515  1514  1513  1512  1511  1510  1509  1508  1507  1506  1505  Older
DateSubjectAuthorDiscuss
03/11/2020
12:16
Well, in the absence of tangible news, one thing is for sure.When the open offer placing shares hit the market tomorrow, there won't be the usual sell off and associated drop in price.There can't be, there is no profit to take, and it would make no sense.From an investing perspective, the natural direction of travel for this share should now be gently upwards whilst the RNS's are anticipated.
festario
03/11/2020
11:07
Courtesy of Davidbarnes. Numis came out with the following this morning. "with £87 million in gross proceeds the company is now fully funded to complete a single pivotal 900 patient 2 dose phase 3 trial across 20 countries, whilst also scaling up manufacturing to meet anticipated commercial demand.High quality trial design. In raising funds directly the company has greater control of the trial design. This is crucial given criticism of WHO solidarity study. (Paraphrase) SNG will have critical role to play as health systems deal with increased hospitalisations. Expect study to start immediately.Scientific logic remains strong, Interferon delivery to lungs aids bodies first defence,more effective than Remdesvir, they see important role as first phase vaccines may not be effective. Final paragraph as before, how can you value a drug with such potential, base case 990 bull case 5000.
blakieboy7
03/11/2020
10:26
Could I have a coin for the guild too please Nobby?
sandcrab2
Chat Pages: Latest  1516  1515  1514  1513  1512  1511  1510  1509  1508  1507  1506  1505  Older

Your Recent History

Delayed Upgrade Clock